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Introduction: More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and
several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are
differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for
several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk
of BC subtypes in BRCA1 and BRCA2 carriers.
Methods: We used data from 15,252 BRCA1 and 8,211 BRCA2 carriers to analyze the associations between
approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen receptor
(ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and triple-negative- (TN) status;
morphologic subtypes; histological grade; and nodal involvement.
Results: The estimated BC hazard ratios (HRs) for the 74 known BC alleles in BRCA1 carriers exhibited moderate
correlations with the corresponding odds ratios from the general population. However, their associations with
ER-positive BC in BRCA1 carriers were more consistent with the ER-positive associations in the general population
(intraclass correlation (ICC) = 0.61, 95% confidence interval (CI): 0.45 to 0.74), and the same was true when considering
ER-negative associations in both groups (ICC = 0.59, 95% CI: 0.42 to 0.72). Similarly, there was strong correlation between
the ER-positive associations for BRCA1 and BRCA2 carriers (ICC = 0.67, 95% CI: 0.52 to 0.78), whereas ER-positive
associations in any one of the groups were generally inconsistent with ER-negative associations in any of the others.
After stratifying by ER status in mutation carriers, additional significant associations were observed. Several previously
unreported variants exhibited associations at P <10−6 in the analyses by PR status, HER2 status, TN phenotype,
morphologic subtypes, histological grade and nodal involvement.
Conclusions: Differences in associations of common BC susceptibility alleles between BRCA1 and BRCA2 carriers and
the general population are explained to a large extent by differences in the prevalence of ER-positive and ER-negative
tumors. Estimates of the risks associated with these variants based on population-based studies are likely to be
applicable to mutation carriers after taking ER status into account, which has implications for risk prediction.Introduction
Women who carry pathogenic mutations in BRCA1 or
BRCA2 have markedly increased risks of developing
breast cancer. The distributions of breast cancer tumor
characteristics differ between BRCA1 mutation carriers,
BRCA2 mutation carriers and those arising in the gen-
eral population. The majority of breast tumors arising in
BRCA1 carriers show low or absent expression of estro-
gen receptor (ER) [1-3], whereas the majority of BRCA2-
associated tumors are ER-positive [1,4,5].
Many common breast cancer susceptibility alleles iden-
tified through population-based genome-wide association
studies (GWASs) have also been associated with breast
cancer risk in BRCA1 and BRCA2 carriers [6,7]. Several of
these variants are specifically associated with the ER status
of the breast cancer in the general population [8,9].
Among the single-nucleotide polymorphisms (SNPs) that
have been evaluated in mutation carriers so far, thevariants found to be associated with breast cancer risk for
BRCA1 carriers largely overlap with loci for which stron-
ger associations with ER-negative breast cancer have been
reported in the general population [8-12]. An important
question for risk modelling and prevention studies is
whether the effects of common variants on breast cancer
risk in mutation carriers are mediated through a generic
influence on the development of particular hormone re-
ceptor subtypes of breast cancer or through epistatic inter-
action with the BRCA1/2 mutation itself.
Previous studies by the Consortium of Investigators of
Modifiers of BRCA1/2 (CIMBA) described the impact
of 29 breast cancer susceptibility variants from non-
hereditary breast cancer studies on ER-positive and ER-
negative breast cancer risk in BRCA1 and BRCA2
carriers [6,7,13-15]. These analyses demonstrated that,
despite the lack of an association between some suscep-
tibility variants and overall breast cancer risk for BRCA1
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cific disease subtypes. In addition, the ER-specific asso-
ciations in BRCA1 and BRCA2 carriers were mainly in
the same direction and of a magnitude similar to the as-
sociations observed with breast cancer stratified by ER
expression status in the general population. However,
these studies were conducted on smaller numbers of
mutation carriers than currently available and evaluated
only a subset of the currently known breast cancer sus-
ceptibility alleles for their associations with ER-specific
subtypes in carriers. Recently, 45 additional SNPs have
been found to be associated with breast cancer risk in
the general population [8-10,16]. Eighteen of these SNPs
showed evidence of association with ER-positive breast
cancer, but not with ER-negative breast cancer, and four
loci (1q32.1 LGR6, 2p24.1, 16q12 and 20q11) were asso-
ciated only with ER-negative breast cancer in the gen-
eral population. These 45 newly discovered loci have
not yet been evaluated for their associations with breast
cancer risk for mutation carriers.
In the present study, we assessed the disease subtype-
specific associations of all 74 previously reported breast
cancer susceptibility variants in 15,252 BRCA1 and
8,211 BRCA2 carriers. We evaluated whether differences
in associations of known breast cancer susceptibility var-
iants between BRCA1 carriers, BRCA2 carriers and the
general population are mediated by tumor ER status in
mutation carriers. We also analyzed the associations of
about 200,000 variants on the iCOGS genotyping array
with subtype-specific breast cancer risk in carriers in an
attempt to uncover previously unreported subtype-
specific associations in women with BRCA1 and BRCA2
mutations. In addition to ER and progesterone receptor
(PR) status, we report, for the first time to our know-
ledge, associations by HER2 status and with triple-
negative disease (TN, referring to ER-, PR- and human
epidermal growth factor receptor 2 (HER2)-negative),
and we also describe associations with clinical features
such as “ductal, no specified subtype” (hereafter referred
to as ductal) and lobular morphologic subtypes, nodal
status and histological grade.
Methods
Study subjects
Data were obtained from 47 studies in 27 different coun-
tries in CIMBA [17]. Eligible study subjects were women
who carry pathogenic mutations in BRCA1 or BRCA2.
The majority were recruited through cancer genetics
clinics and enrolled into national or regional studies.
Written informed consent was obtained from all sub-
jects. Each of the host institutions recruited under ethic-
ally approved protocols. A list of the local institutional
review boards that provided ethical approval for this
study is given in Additional file 1: Table S1. Eligibilitywas restricted to mutation carriers who were 18 years
of age or older at recruitment. Data collected included
year of birth, age at cancer diagnosis, personal history
of bilateral prophylactic mastectomy and/or bilateral
salpingo-oophorectomy, mutation description, tumor
pathology and ethnicity.
Tumor pathology data
Breast tumor pathology data were gathered from a range
of sources, specifically patient pathology reports, path-
ology review data, tumor registry records and tissue
microarray results. These included information on ER,
PR and HER2 status; morphologic subtype; lymph node
involvement; and histological grade. For ER, PR and
HER2, status was classified as negative or positive, with
supplementary immunohistochemistry scoring or bio-
chemical data and methodology provided when available.
The vast majority of centers employed a cutoff of either
≥10% or ≥1% of tumor nuclei staining positive to define
ER and PR positivity. Additional file 1: Table S2 lists the
subtype definitions used by each study, which were not
centrally reclassified, owing to the low proportion of re-
cords with supporting staining data. Similarly, HER2 sta-
tus was determined using immunohistochemistry to
detect strong complete membrane staining (with a score
of 3+ considered positive) and/or in situ hybridization to
detect HER2 gene amplification. To ensure consistency
across studies, when information on the cells stained
was available, we used the same cutoff to define ER-,
PR- and HER2-positive tumors. The cutoffs used for the
small number of cases where composite scoring methods
based on the proportion and intensity of staining were
available (Allred score, immunoreactive Remmele score)
are given in Additional file 1: Table S2. Consistency
checks were performed to validate receptor data against
supplementary scoring information, if provided. Each
cancer was assigned to a morphologic subgroup (ductal,
lobular, medullary, other), which we confirmed using the
World Health Organization International Classification
of Diseases for Oncology (ICD-O) code for the classifi-
cation of tumor type when sufficient information was
provided [18]. Lymph node status, along with the num-
ber of nodes showing metastatic carcinoma, was pro-
vided when available. Histologic grade was assigned as
grade 1, 2 or 3 by local pathologists who used a modified
Scarff-Bloom-Richardson malignancy grading system.
Genotyping and quality control
Genotyping was carried out using the iCOGS custom
array. The array development and details of the genotyp-
ing and quality control for the CIMBA samples are de-
scribed in detail elsewhere [6,7]. Briefly, genotyping for
BRCA2 carriers was conducted at McGill University and
Génome Québec Innovation Centre (Canada) and for
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excluded if they were located on the Y chromosome, if
they were monomorphic, if they deviated significantly
from Hardy-Weinberg equilibrium (P <10−7) or if they
had call rates <95%. Samples were excluded if they had a
call rate <95%, if they were of non-European ancestry or
if they demonstrated extreme heterozygosity. After qual-
ity control, we had 200,720 SNPs available for analysis in
15,252 BRCA1 samples and 200,908 SNPs available for
analysis in 8,211 BRCA2 samples.
Statistical methods
We evaluated the associations of each genotype with risks
of developing breast cancer or breast cancer subtypes de-
fined by the tumor characteristics or morphology. The
analyses were carried out within a survival analysis frame-
work. Individuals were censored at the first of the fol-
lowing events: breast cancer diagnosis, ovarian cancer
diagnosis, bilateral mastectomy or age at last follow-up. In
order to account for non-random ascertainment of muta-
tion carriers with respect to their disease phenotype, we
used a retrospective likelihood approach that models the
probability of observing the genotypes conditional on the
disease phenotype [19,20]. It was assumed that the cancer
incidence depends on the underlying SNP genotype
through a Cox proportional hazards model:
λi tið Þ ¼ λ0 tið Þ exp βzið Þ;
where λ0(ti) is the baseline incidence and β is the loga-
rithm of the per-allele hazard ratio (HR, under a multi-
plicative model). The association with overall breast
cancer risk was evaluated by testing the hypothesis that
β = 0 [20].
We evaluated the associations with the groups of each
subtype class (for example, ER-positive and ER-negative),
using an extension of the retrospective likelihood ap-
proach to model the simultaneous effect of each SNP on
more than one tumor subtype [15]. Briefly, this involves
modeling the conditional likelihood of the observed SNP
genotypes and tumor subtypes, given the disease pheno-
types. Within this framework, it is possible to estimate
simultaneously the HRs for each tumor subtype and test
for heterogeneity in the associations [15]. To maximize
the available information, genotyped mutation carriers
that were missing information on tumor characteristics
were included in the analysis, and their disease subtype
was assumed to be missing at random. In order to account
for non-independence among relatives, a robust variance
estimation approach was used [20]. Further details of the
methods for evaluating the associations with overall breast
cancer [20] and tumor subtypes have been described else-
where [15]. We carried out association analyses by subtype
for the following breast cancer characteristics: ER-positiveand ER-negative, PR-positive and PR-negative, HER2-
positive and HER2-negative, TN breast cancer (that is,
negative for ER, PR and HER2) and non-TN (that is,
tumor positive for at least one of the three receptors),
ductal morphologic subtype, lobular morphologic subtype,
nodal involvement (no involved lymph nodes and at least
one involved lymph node) and histological grade (high
grade (grade 3) and non-high grade (grades 1 and 2)).
Only samples with complete information on ER, PR and
HER2 expression were included in the analysis for TN as
well as non-TN breast cancer. The SNP associations by
tumor morphologic subtype were evaluated by comparing
ductal tumors to all others and, in a separate analysis,
lobular tumors to all others. We are not reporting associ-
ation analyses for risk of medullary morphologic subtype,
owing to sparse data as well as the difficulties in diagnos-
ing medullary breast tumors reliably [21,22]. All analyses
were stratified by country of residence. The United States
and Canada strata were further subdivided by reported
Ashkenazi Jewish ancestry. For subtypes with small
groups, strata of geographically close countries were com-
bined to provide sufficiently large groups for estimation.
All analyses used calendar year– and cohort-specific can-
cer incidences for BRCA1 and BRCA2. SNPs with minor
allele frequencies <3% were excluded. The retrospective
likelihood was modeled using custom-written functions im-
plemented in the pedigree analysis software MENDEL [23].
When evaluating whether the known breast cancer
susceptibility loci identified through population based
studies also modify breast cancer risk in mutation car-
riers, a significance threshold of P <0.05 was used be-
cause of the strong prior evidence of association for
these loci with disease risk. For the association analyses
of all the approximately 200,000 variants on the iCOGS
array with the breast cancer subtypes in mutation car-
riers, only associations with P < 5 × 10−8 were considered
significant. The discussion of findings and the tables
were extended to associations at P <10−6.
For variants associated with ER-positive or ER-negative
breast cancer with P <0.01, we evaluated whether the asso-
ciations may have been affected by a possible survival bias
due to inclusion of prevalent breast cancer cases in the
analysis. For the sensitivity analysis, the association ana-
lysis by ER status was repeated after excluding mutation
carriers diagnosed with breast cancer ≥5 years prior to
study recruitment.
We evaluated the consistency between the breast can-
cer association estimates of previously reported breast
cancer susceptibility variants in the general population
(using published data) and the association estimates in
BRCA1 and BRCA2 carriers using the intraclass correl-
ation (ICC). We estimated ICC as outlined by Shrout and
Fleiss [24] based on a one-way random-effects model and
tested for agreement in absolute values of log HR. The
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tween associations with ER-positive and/or -negative
breast cancer in the general population and associations
with ER-positive and/or -negative breast cancer in BRCA1
and in BRCA2 carriers. Furthermore, we carried out the
same comparisons between associations for BRCA1 and
associations for BRCA2 carriers.
Results
Subtype patterns
The analyses included data from 15,252 BRCA1 carriers
and 8,211 BRCA2 carriers. Among the breast cancer–
affected BRCA1 carriers, we had data on at least one
disease characteristic of interest for 4,619 (59%) of the
7,797 affected women (Table 1). Data were available on
tumor characteristics for 2,570 (59%) of the 4,330 af-
fected BRCA2 carriers. Of the individuals with path-
ology information, 74% of the BRCA1 carriers and 75%
of the BRCA2 carriers had data on ER status.
Single-nucleotide polymorphism associations
After quality control, genotype data were available for
analysis for 200,720 SNPs for BRCA1 carriers and forTable 1 Breast tumor characteristics of 7,797 affected BRCA1
carriersa
BRCA1 mutation carriers
Yes, n (%) No, n (%) Unknown
Predictive markers
ER-positive 819 (24) 2,639 (76) 4,339
PR-positive 662 (21) 2,485 (79) 4,650
HER2-positive 182 (9) 1,816 (91) 5799
Non-TN 580 (31) 1,310 (69) 5907
Morphology 3,789
Ductal 3,159 (82)
Lobular 89 (2)
Medullary 290 (6)
Other 470 (10)
Grade 4,645
Grade 1 81 (3)
Grade 2 574 (18)
Grade 3 2,497 (79)
Nodal involvement 1,103 (33) 2,274 (67) 4,420
Stage 5,991
Stage 0b 65 (4)
Stage 1 825 (46)
Stage 2 772 (43)
Stage 3 127 (7)
Stage 4 17 (1)
aER, Estrogen receptor positive; HER2, Human epidermal growth factor receptor 2; P200,908 SNPs for BRCA2 carriers. After adjusting for
sample size and excluding SNPs chosen for inclusion on
the genotyping array based on reported associations in
subsets of the current sample, the inflation coefficient
λ1000 values were 1.01 for ER-positive disease in BRCA1
carriers, 1.02 for ER-negative in BRCA1, 1.01 for ER-
positive in BRCA2 and 1.02 for ER-negative in BRCA2
carriers (Additional file 1: Figure S1 and Figure S2).
Similar patterns were observed for other tumor charac-
teristics (results not shown). After excluding variants lo-
cated at known breast cancer susceptibility loci, there
was no evidence for an excess in associations by ER sta-
tus beyond the number expected.
Associations of previously reported breast cancer
susceptibility loci
Associations with overall breast cancer and by tumor
estrogen receptor status
First, we considered the associations with risk for overall
breast cancer and for tumor subtypes for the 74 breast
cancer susceptibility variants that have been reported up
to April 2013. In light of the strong prior evidence of
association, we considered associations at P <0.05 asmutation carriers and 4,330 affected BRCA2 mutation
BRCA2 mutation carriers
status Yes, n (%) No, n (%) Unknown status
1,490 (77) 434 (23) 2,406
1,099 (65) 591 (35) 2,640
121 (13) 847 (87) 3,362
760 (85) 136 (15) 3,434
2,087
1,770 (79)
188 (8)
39 (2)
246 (11)
3,840
113 (7)
700 (42)
839 (51)
804 (43) 1,068 (57) 2,458
3,382
121 (13)
327 (35)
390 (41)
96 (10)
14 (1)
R, Progesterone receptor; TN, Triple-negative. bCarcinoma in situ.
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ceptibility allele also modifies overall or ER-specific
breast cancer risk in mutation carriers. The associations
with overall breast cancer risk and risk of breast cancer
subtypes for all 74 variants are given in Table 2 and
Additional file 1: Tables S4 to S10. Of the breast cancer
susceptibility loci that had not previously been evaluated
for an association in mutation carriers, SNPs at 5q33.3,
8q24.21, 11q24.3, 12q22, 16q12.1, 22q13.1 were associ-
ated with overall breast cancer risk for BRCA1 carriers,
and SNPs at 6p23, 11q24.3 and 16q12.1 were associated
with breast cancer risk for BRCA2 carriers at P <0.05
(Table 2). Overall, 15 breast cancer susceptibility variants
were associated with ER-negative breast cancer in BRCA1
carriers and 8 variants in BRCA2 carriers at P <0.05
(Table 2). Ten significant associations with ER-positive
breast cancer in BRCA1 carriers and fourteen in BRCA2
carriers were found. The strongest association with ER-
positive breast cancer was observed for rs2981579 in
FGFR2 at 10q26.12 for both BRCA1 and BRCA2 carriers.
SNP rs10069690 in TERT at 5p15.33 displayed the stron-
gest association with ER-negative breast cancer for BRCA1
carriers and rs9348512 at 6p24.3 for BRCA2 carriers. We
found significant differences in the associations by ER sta-
tus for rs3803662 in TOX3 at 16q12.1 (P = 2 × 10−4) and
rs13387042 at 2q35 (P =0.002) for BRCA1 carriers, which
were not previously seen. Both SNPs showed evidence of
association with ER-positive breast cancer only. Similarly,
six of the loci that did not show evidence of association
with overall breast cancer were associated with ER-
positive and two with ER-negative breast cancer in BRCA1
carriers. This included two of the loci not previously eval-
uated in mutation carriers: 3q26.1 and 6p25.3. In BRCA2
carriers, four of the variants lacking evidence of associ-
ation with overall breast cancer were associated with ER-
negative and three with ER-positive breast cancer. This
included four loci not previously evaluated in mutation
carriers: 2q24, 14q13.3, 19q13.31 and 22q12.2. Of the
breast cancer susceptibility loci that had not yet been eval-
uated for an association with breast cancer in mutation
carriers, rs1011970 at CDKN2A/B and rs1292011 at
12q24.21 had significantly different associations with ER-
positive and ER-negative cancer for BRCA1 carriers (Phet =
0.009 and Phet = 0.004, respectively, for the difference be-
tween ER-positive and ER-negative). SNP rs2236007 at
14q13.3 displayed differences by ER status for BRCA2 car-
riers (Phet = 0.008). These three SNPs had associations in
different directions for ER-positive and ER-negative
tumors.
When association analyses for ER-positive and -negative
disease were repeated after excluding prevalent breast
cancer cases (Additional file 1: Table S3), the HR estimates
were consistent with the estimates from the complete
sample but were associated with larger confidenceintervals. Therefore, it is unlikely that our results are influ-
enced by survival bias.
Associations with other subtypes and clinical features
The pattern of associations of previously reported breast
cancer susceptibility variants by PR and TN status were
very similar to that by ER status (Additional file 1:
Tables S4 and S6), but fewer associations were observed
at P <0.01. SNP rs720475 at 7q35 was the only variant
that was associated with HER2-positive disease (HR =
1.45 and P = 0.003 for HER2-positive, Phet = 9 × 10
−4 in
BRCA2 carriers) (Additional file 1: Table S5).
For BRCA1 carriers, there were significant differences
(Phet <0.01) in the HR for high grade (grade 3) and
grades 1 and 2 breast cancer for SNPs at 10q26.12
(FGFR2) and at 12q24.21 (Additional file 1: Table S9).
SNP rs3803662 in TOX3 at 16q12.1 was associated ex-
clusively with node-positive breast cancer (P = 2 × 10−4,
Phet = 0.005) (Additional file 1: Table S10). This was also
the only variant associated with lobular cancer, as shown
in Additional file 1: Table S8 (P = 8 × 10−6 for BRCA2
carriers). The HR for lobular cancer was larger than that
for non-lobular cancer (lobular HR = 1.57, 95% CI: 1.29
to 1.92; non-lobular HR = 1.20, 95% CI: 1.13 to 1.28 for
BRCA2 carriers; Phet = 9 × 10
−4). There was no evidence
for differences in associations by histological grade and
nodal involvement for BRCA2 carriers.
Comparison of patterns of associations by breast cancer
estrogen receptor status between BRCA1 and BRCA2
carriers and the general population
We compared the log HR estimates for the breast cancer
association of known breast cancer susceptibility variants
for BRCA1 carriers, BRCA2 carriers, and for the general
population using published data from the Breast Cancer
Association Consortium (BCAC) [8]. The resulting ICC
coefficients for log HR/OR estimates for all comparisons
are shown in Table 3. Log HR estimates for overall
breast cancer risk in BRCA2 carriers were very similar to
the log odds ratios (ORs) from the general population
(ICC = 0.63, 95% CI: 0.47 to 0.75) (Additional file 1:
Figure S3B), whereas there was only moderate correl-
ation between the log HR estimates for BRCA1 carriers
and the log HR estimates from both other groups (ICC:
BRCA1-BCAC estimates = 0.43, BRCA1-BRCA2 = 0.46)
(Additional file 1: Figure S3A,C). When comparing ER-
positive specific associations, we found stronger agree-
ment between the log HR/OR estimates than for overall
breast cancer. The ICC estimates ranged from 0.61 (95%
CI: 0.45 to 0.74) (Figure 1B) for BCAC-BRCA1 to 0.69
(95% CI: 0.55 to 0.79) (Figure 1C) for BCAC-BRCA2.
The ER-negative breast cancer log HR estimates in
BRCA1 carriers and the corresponding BCAC estimates
were strongly correlated (ICC = 0.59, 95% CI: 0.42 to
Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancera
BRCA1 carriers
Overall ER-negative ER-positive
Locus SNP Positionb Nearby
gene
Refc Effd Ke MAF HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value Phet-value
f
1p36.22 rs616488 10566215 PEX14 A G No 0.32 0.96 (0.92 to 1.01) 0.10 0.95 (0.90 to 1.00) 0.07 1.00 (0.90 to 1.10) 0.92 0.47
1p13.2 rs12022378 114448389 SYT6 G A No 0.16 1.03 (0.98 to 1.09) 0.25 1.03 (0.97 to 1.10) 0.31 1.03 (0.90 to 1.17) 0.68 0.94
1p11.2 rs11249433 121280613 FCGR1B A G Yes 0.41 0.99 (0.95 to 1.04) 0.78 0.99 (0.94 to 1.03) 0.55 1.02 (0.93 to 1.13) 0.63 0.50
1q32.1a rs6678914 202187176 LGR6 G A No 0.4 0.98 (0.94 to 1.02) 0.39 0.96 (0.91 to 1.01) 0.08 1.06 (0.97 to 1.17) 0.21 0.07
1q32.1b rs4245739 204518842 MDM4 A C Yes 0.28 1.10 (1.05 to 1.15) 4.6 × 10−5 1.12 (1.07 to 1.19) 1.4 × 10−5 1.02 (0.91 to 1.13) 0.76 0.11
2p24.1 rs12710696 19320803 OSR1 G A No 0.39 1.01 (0.97 to 1.06) 0.51 1.01 (0.97 to 1.07) 0.57 1.01 (0.92 to 1.12) 0.77 1.00
2q14.2 rs4849887 121245122 G A No 0.11 1.02 (0.96 to 1.09) 0.53 1.01 (0.94 to 1.09) 0.78 1.05(0.90 to 1.23) 0.49 0.64
2q31.1 rs2016394 172972971 DLX2 G A No 0.47 1.01 (0.97 to 1.06) 0.54 1.03 (0.98 to 1.08) 0.23 0.96 (0.87 to 1.06) 0.39 0.21
2q31.1 rs1550623 174212894 CDCA7 A G No 0.15 1.01 (0.95 to 1.07) 0.72 1.02 (0.95 to 1.09) 0.54 0.97 (0.85 to 1.12) 0.72 0.57
2q35 rs13387042 217905832 TNP1 A G Yes 0.47 0.98 (0.94 to 1.02) 0.41 1.02 (0.97 to 1.07) 0.37 0.86 (0.78 to 0.95) 1.9 × 10−3 2.3 × 10−3
2q35 rs16857609 218296508 DIRC3 G A No 0.26 1.04 (1.00 to 1.09) 0.06 1.03 (0.98 to 1.09) 0.23 1.08 (0.97 to 1.21) 0.14 0.47
3p26.1 rs6762644 4742276 ITPR1 A G No 0.36 1.04 (0.99 to 1.08) 0.09 1.00 (0.95 to 1.05) 0.92 1.16 (1.05 to 1.28) 2.9 × 10−3 0.01
3p24.1 rs4973768 27416013 SLC4A7 G A Yes 0.49 1.01 (0.97 to 1.06) 0.47 0.99 (0.95 to 1.04) 0.81 1.09 (0.99 to 1.19) 0.07 0.10
3p24.1 rs12493607 30682939 TGFBR2 C G No 0.35 0.99 (0.95 to 1.04) 0.73 0.99 (0.94 to 1.04) 0.63 1.01 (0.92 to 1.11) 0.85 0.70
4q24 rs9790517 106084778 TET2 G A No 0.23 0.98 (0.94 to 1.03) 0.51 0.97 (0.92 to 1.03) 0.30 1.03 (0.92 to 1.15) 0.61 0.37
4q34.1 rs6828523 175846426 EBF1 C A No 0.11 1.03 (0.96 to 1.1) 0.41 1.03 (0.95 to 1.11) 0.47 1.02 (0.88 to 1.19) 0.78 0.94
5p15.33 rs10069690 1279790 TERT G A Yes 0.28 1.21 (1.15 to 1.26) 1.1 × 10−15 1.24 (1.18 to 1.31) 2.7 × 10−15 1.09 (0.98 to 1.22) 0.09 0.04
5p15.33 rs7725218 1282414 TERT G A Yes 0.36 1.08 (1.04 to 1.13) 3.2 × 10−4 1.09 (1.04 to 1.15) 6.4 × 10−4 1.05 (0.95 to 1.15) 0.37 0.47
5p15.33 rs2736108 1297488 TERT G A Yes 0.29 0.89 (0.85 to 0.93) 4.2 × 10−7 0.86 (0.82 to 0.91) 1.1 × 10−7 0.98 (0.88 to 1.08) 0.68 0.04
5p12 rs10941679 44706498 MRPS30 A G Yes 0.25 0.99 (0.94 to 1.04) 0.61 0.99 (0.94 to 1.05) 0.84 0.97 (0.86 to 1.08) 0.54 0.66
5q11.2 rs889312 56031884 MAP3K1 A C Yes 0.29 1.01 (0.97 to 1.06) 0.52 0.99 (0.94 to 1.05) 0.82 1.09 (0.98 to 1.21) 0.12 0.15
5q11.3 rs10472076 58184061 RAB3C A G No 0.37 1.00 (0.96 to 1.05) 0.83 0.98 (0.94 to 1.03) 0.52 1.08 (0.98 to 1.18) 0.13 0.11
5q11.3 rs1353747 58337481 PDE4D A C No 0.09 0.98 (0.91 to 1.05) 0.53 0.95 (0.88 to 1.04) 0.28 1.06 (0.90 to 1.24) 0.50 0.29
5q33.3 rs1432679 158244083 A G No 0.44 1.05 (1.00 to 1.09) 0.03 1.03 (0.98 to 1.08) 0.25 1.10 (1.01 to 1.21) 0.04 0.21
6p25.3 rs11242675 1318878 FOXQ1 A G No 0.35 0.96 (0.92 to 1) 0.06 0.94 (0.90 to 0.99) 0.03 1.01 (0.91 to 1.11) 0.90 0.28
6p24.3 rs9348512 10456706 TFAP2A C A Yes 0.34 1.00 (0.95 to 1.04) 0.87 1.00 (0.95 to 1.05) 0.88 1.00 (0.90 to 1.10) 0.95 1.00
6p23 rs204247 13722523 RANBP9 A G No 0.44 1.00 (0.96 to 1.04) 0.98 1.00 (0.95 to 1.04) 0.84 1.01 (0.92 to 1.12) 0.75 0.72
6q14 rs17530068 82193109 FAM46A A G Yes 0.25 1.03 (0.98 to 1.08) 0.23 1.03 (0.97 to 1.09) 0.29 1.03 (0.92 to 1.14) 0.63 0.95
6q25.1 rs3757318 151914113 ESR1 G A Yes 0.08 1.20 (1.11 to 1.29) 1.1 × 10−6 1.24 (1.14 to 1.35) 5.6 × 10−7 1.06 (0.89 to 1.26) 0.51 0.12
6q25.1 rs2046210 151948366 ESR1 G A Yes 0.37 1.16 (1.12 to 1.21) 2.4 × 10−12 1.20 (1.15 to 1.26) 2.8 × 10−13 1.04 (0.94 to 1.15) 0.42 0.01
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Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancera (Continued)
7q35 rs720475 144074929 ARHGEF5 G A Yes 0.26 0.98 (0.93 to 1.03) 0.36 0.98 (0.93 to 1.04) 0.54 0.96 (0.86 to 1.08) 0.53 0.79
8p12 rs9693444 29509616 DUSP4 C A Yes 0.33 1.01 (0.96 to 1.05) 0.80 1.01 (0.96 to 1.06) 0.69 0.99 (0.90 to 1.09) 0.83 0.72
8q21.11 rs6472903 76230301 A C Yes 0.17 1.01 (0.96 to 1.07) 0.74 1.01 (0.95 to 1.08) 0.77 1.01 (0.89 to 1.14) 0.89 0.99
8q21.11 rs2943559 76417937 HNF4G A G Yes 0.08 1.06 (0.98 to 1.14) 0.12 1.07 (0.98 to 1.17) 0.12 1.02 (0.86 to 1.22) 0.78 0.68
8q24.21 rs11780156 129194641 MYC G A No 0.19 0.95 (0.9 to 1) 0.05 0.96 (0.90 to 1.02) 0.15 0.93 (0.82 to 1.05) 0.23 0.70
8q24.21 rs13281615 128355618 A G Yes 0.43 1.02 (0.98 to 1.06) 0.44 1.01 (0.96 to 1.06) 0.73 1.04 (0.95 to 1.15) 0.38 0.55
9p21.3 rs1011970 22062134 CDKN2B C A Yes 0.17 1.02 (0.97 to 1.08) 0.47 1.07 (1.00 to 1.14) 0.05 0.87 (0.76 to 0.99) 0.04 9.3 × 10−3
9q31.2 rs10759243 110306115 KLF4 C A No 0.31 0.98 (0.94 to 1.02) 0.39 0.98 (0.93 to 1.03) 0.49 0.98 (0.88 to 1.08) 0.64 0.93
9q31.2 rs865686 110888478 KLF4 A C Yes 0.36 0.99 (0.95 to 1.04) 0.77 1.02 (0.97 to 1.07) 0.52 0.92 (0.83 to 1.02) 0.11 0.10
10p12.31 rs7072776 22032942 MLLT10 G A No 0.31 0.99 (0.94 to 1.03) 0.52 0.96 (0.91 to 1.01) 0.11 1.08 (0.98 to 1.20) 0.12 0.04
10p12.31 rs11814448 22315843 DNAJC1 A C No 0.02 1.10 (0.94 to 1.29) 0.22 1.25 (0.93 to 1.69) 0.15 0.50
10q21.2 rs10995190 64278682 ZNF365 G A Yes 0.15 0.99 (0.93 to 1.05) 0.70 1.02 (0.96 to 1.09) 0.49 0.88 (0.76 to 1.00) 0.06 0.05
10q22.3 rs704010 80841148 ZMIZ1 G A Yes 0.37 1.01 (0.97 to 1.06) 0.48 0.99(0.94 to 1.04) 0.61 1.12 (1.01 to 1.23) 0.03 0.03
10q25.2 rs7904519 114773927 TCF7L2 A G Yes 0.47 1.09 (1.05 to 1.14) 1.6 × 10−5 1.09 (1.04 to 1.14) 6.4 × 10−4 1.12 (1.02 to 1.23) 0.02 0.59
10q26.12 rs2981579 123337335 FGFR2 G A Yes 0.42 0.99 (0.95 to 1.04) 0.81 0.92 (0.87 to 0.96) 6.9 × 10−4 1.29 (1.17 to 1.43) 3.1 × 10−7 7.5 × 10−9
10q26.12 rs11199914 123093901 FGFR2 G A No 0.33 1.02 (0.98 to 1.07) 0.27 1.04 (0.99 to 1.10) 0.09 0.96 (0.86 to 1.06) 0.43 0.17
11p15.5 rs3817198 1909006 LSP1 A G Yes 0.33 1.08 (1.03 to 1.13) 6.5 × 10−4 1.08 (1.03 to 1.14) 2.9 × 10−3 1.07 (0.97 to 1.18) 0.17 0.89
11q13.1 rs3903072 65583066 SNX32 C A No 0.47 0.99 (0.95 to 1.03) 0.69 1.00 (0.95 to 1.05) 0.94 0.96 (0.87 to 1.05) 0.39 0.44
11q13.3 rs554219 69331642 CCND1 C G Yes 0.12 1.03 (0.97 to 1.09) 0.37 1.00 (0.93 to 1.08) 0.96 1.12 (0.97 to 1.29) 0.12 0.20
11q13.3 c11_pos690
88342
69379161 C A Yes 0.06 1.03 (0.95 to 1.13) 0.45 1.00 (0.90 to 1.12) 0.95 1.14 (0.93 to 1.39) 0.20 0.30
11q13.3 rs494406 69344241 G A Yes 0.25 1.02 (0.97 to 1.07) 0.46 1.02 (0.97 to 1.08) 0.42 1.00 (0.90 to 1.12) 0.97 0.74
11q24.3 rs11820646 129461171 BARX2 G A No 0.39 0.93 (0.89 to 0.97) 5.9 × 10−4 0.94 (0.90 to 0.99) 0.03 0.88 (0.79 to 0.97) 8.9 × 10−3 0.20
12p13.1 rs12422552 14413931 ATF7IP G C No 0.27 1.01 (0.97 to 1.06) 0.63 1.01 (0.96 to 1.07) 0.68 1.01 (0.91 to 1.13) 0.85 0.99
12p11.22 rs10771399 28155080 PTHLH A G Yes 0.10 0.85 (0.80 to 0.91) 1.9 × 10−6 0.83 (0.77 to 0.9) 1.2 × 10−5 0.91 (0.78 to 1.06) 0.24 0.36
12q22 rs17356907 96027759 NTN4 A G No 0.29 0.95 (0.91 to 1.00) 0.03 0.94 (0.90 to 1.00) 0.03 0.98 (0.88 to 1.09) 0.71 0.56
12q24.21 rs1292011 115836522 TBX3 A G Yes 0.41 1.00 (0.96 to 1.05) 0.82 1.04 (0.99 to 1.10) 0.08 0.88 (0.80 to 0.97) 0.01 4.39 × 10−3
13q13.1 rs11571833 32972626 BRCA2 T A No 0.01 1.02 (0.83 to 1.26) 0.83 1.05 (0.83 to 1.34) 0.66 0.92 (0.53 to 1.59) 0.75 0.66
14q13.3 rs2236007 37132769 PAX9 G A No 0.21 0.97 (0.92 to 1.02) 0.19 0.95 (0.90 to 1.01) 0.13 1.01 (0.90 to 1.14) 0.87 0.42
14q24.1 rs2588809 68660428 G A No 0.19 0.96 (0.91 to 1.01) 0.09 0.95 (0.89 to 1.01) 0.13 0.97 (0.86 to 1.09) 0.56 0.85
14q24.1 rs999737 69034682 RAD51L1 G A Yes 0.21 0.96 (0.91 to 1.01) 0.09 0.98 (0.92 to 1.04) 0.43 0.90 (0.80 to 1.01) 0.07 0.22
14q32.11 rs941764 91841069 CCDC88C A G No 0.34 1.03 (0.98 to 1.07) 0.23 1.02 (0.97 to 1.07) 0.47 1.05 (0.95 to 1.17) 0.34 0.62
16q12.1a rs3803662 52586341 TOX3 G A Yes 0.29 1.06 (1.01 to 1.11) 0.02 1.01 (0.96 to 1.07) 0.65 1.22 (1.10 to 1.35) 1.5 × 10−4 2.39 × 10−3
16q12.1b rs11075995 53855291 FTO A T No 0.24 1.01 (0.96 to 1.06) 0.61 0.98 (0.93 to 1.04) 0.60 1.11 (0.99 to 1.24) 0.07 0.07
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Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancera (Continued)
16q12.1b rs17817449 53813367 FTO A C No 0.41 0.95 (0.91 to 0.99) 0.02 0.94 (0.89 to 0.98) 9.8 × 10−3 1.00 (0.91 to 1.10) 0.99 0.26
16q23.2 rs13329835 80650805 CDYL2 A G No 0.23 1.04 (0.99 to 1.09) 0.09 1.03 (0.97 to 1.09) 0.29 1.08 (0.97 to 1.21) 0.17 0.48
17q22 rs6504950 53056471 COX11 G A Yes 0.27 0.98 (0.94 to 1.03) 0.49 0.99 (0.94 to 1.04) 0.70 0.96 (0.87 to 1.07) 0.49 0.68
18q11.2 rs527616 24337424 AQP4 C G No 0.37 0.99 (0.95 to 1.03) 0.61 0.97 (0.93 to 1.02) 0.30 1.04 (0.94 to 1.15) 0.42 0.26
18q11.2 rs1436904 22824665 A C No 0.39 0.99 (0.95 to 1.03) 0.68 1.00 (0.95 to 1.05) 0.86 0.98 (0.89 to 1.08) 0.63 0.74
19p13.11 rs8170 17389704 BABAM1 G A Yes 0.19 1.19 (1.12 to 1.25) 2.9 × 10−10 1.22 (1.15 to 1.30) 1.7 × 10−10 1.06 (0.95 to 1.20) 0.30 0.05
19p13.11 rs4808801 18571141 ELL A G No 0.32 0.98 (0.94 to 1.02) 0.40 0.99 (0.94 to 1.05) 0.81 0.94 (0.85 to 1.04) 0.23 0.35
19q13.31 rs3760982 44286513 KCNN4 G A No 0.46 1.03 (0.99 to 1.08) 0.10 1.03 (0.98 to 1.08) 0.19 1.04 (0.95 to 1.14) 0.41 0.90
21q21.1 rs2823093 16520832 NRIP1 G A Yes 0.27 0.95 (0.91 to 1) 0.04 0.96 (0.91 to 1.02) 0.17 0.92 (0.82 to 1.02) 0.11 0.44
22q12.2 rs132390 29621477 EMID1 A G No 0.03 0.98 (0.87 to 1.1) 0.75 0.93 (0.81 to 1.07) 0.30 1.16 (0.91 to 1.46) 0.23 0.13
22q13.1 rs6001930 40876234 SGSM3 A G No 0.11 1.07 (1.00 to 1.14) 0.03 1.06 (0.98 to 1.15) 0.14 1.11 (0.96 to 1.30) 0.17 0.60
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Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancera (Continued)
BRCA2 carriers
Overall ER-negative ER-positive
Locus SNP Positionb Nearby
gene
Refc Effd Ke MAF HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value Phet-value
f
1p36.22 rs616488 10566215 PEX14 A G No 0.33 0.98 (0.92 to 1.04) 0.52 1.01 (0.88 to 1.16) 0.94 0.97 (0.9 to 1.05) 0.46 0.69
1p13.2 rs12022378 114448389 SYT6 G A No 0.17 1.03 (0.95 to 1.12) 0.42 1.16 (0.97 to 1.37) 0.10 1.00 (0.91 to 1.1) 1.00 0.15
1p11.2 rs11249433 121280613 FCGR1B A G Yes 0.41 1.05 (0.99 to 1.12) 0.09 1.04 (0.91 to 1.19) 0.57 1.06 (0.99 to 1.13) 0.12 0.84
1q32.1a rs6678914 202187176 LGR6 G A No 0.41 1.04 (0.98 to 1.10) 0.19 0.94 (0.82 to 1.08) 0.39 1.07 (1.00 to 1.15) 0.05 0.11
1q32.1b rs4245739 204518842 MDM4 A C Yes 0.28 0.97 (0.91 to 1.04) 0.38 1.09 (0.95 to 1.26) 0.21 0.94 (0.87 to 1.01) 0.10 0.07
2p24.1 rs12710696 19320803 OSR1 G A No 0.38 1.00 (0.94 to 1.06) 0.99 1.14 (1.00 to 1.30) 0.05 0.96 (0.9 to 1.03) 0.28 0.02
2q14.2 rs4849887 121245122 G A No 0.11 0.98 (0.89 to 1.08) 0.72 1.08 (0.87 to 1.33) 0.49 0.96 (0.85 to 1.07) 0.43 0.34
2q31.1 rs2016394 172972971 DLX2 G A No 0.46 0.99 (0.93 to 1.05) 0.74 1.07 (0.94 to 1.22) 0.32 0.97 (0.9 to 1.04) 0.36 0.21
2q31.1 rs1550623 174212894 CDCA7 A G No 0.15 0.97 (0.89 to 1.06) 0.49 1.03 (0.87 to 1.23) 0.70 0.95 (0.87 to 1.05) 0.31 0.41
2q35 rs13387042 217905832 TNP1 A G Yes 0.48 0.99 (0.93 to 1.05) 0.68 0.98 (0.87 to 1.12) 0.82 0.99 (0.93 to 1.06) 0.74 0.96
2q35 rs16857609 218296508 DIRC3 G A No 0.27 0.96 (0.90 to 1.03) 0.26 0.87 (0.74 to 1.01) 0.08 0.99 (0.92 to 1.07) 0.82 0.14
3p26.1 rs6762644 4742276 ITPR1 A G No 0.37 0.98 (0.93 to 1.05) 0.61 1.08 (0.94 to 1.24) 0.27 0.96 (0.89 to 1.03) 0.24 0.13
3p24.1 rs4973768 27416013 SLC4A7 G A Yes 0.5 1.08 (1.02 to 1.15) 7.8 × 10−3 1.05 (0.92 to 1.20) 0.46 1.10 (1.02 to 1.18) 0.01 0.58
3p24.1 rs12493607 30682939 TGFBR2 C G No 0.34 0.98 (0.92 to 1.04) 0.54 1.07 (0.93 to 1.22) 0.35 0.96 (0.89 to 1.03) 0.23 0.17
4q24 rs9790517 106084778 TET2 G A No 0.22 0.97 (0.91 to 1.05) 0.48 0.91 (0.77 to 1.07) 0.25 0.99 (0.91 to 1.08) 0.88 0.35
4q34.1 rs6828523 175846426 EBF1 C A No 0.1 0.98 (0.89 to 1.08) 0.72 1.05 (0.85 to 1.30) 0.64 0.96 (0.86 to 1.08) 0.51 0.49
5p15.33 rs10069690 1279790 TERT G A Yes 0.27 1.11 (1.04 to 1.19) 1.6 × 10−3 1.25 (1.08 to 1.44) 3.2 × 10−3 1.08 (1.00 to 1.17) 0.06 0.09
5p15.33 rs7725218 1282414 TERT G A Yes 0.36 1.06 (0.99 to 1.12) 0.08 1.07 (0.93 to 1.23) 0.35 1.05 (0.98 to 1.13) 0.17 0.85
5p15.33 rs2736108 1297488 TERT G A Yes 0.3 0.93(0.88 to 1.00) 0.04 0.91 (0.78 to 1.05) 0.20 0.94 (0.87 to 1.02) 0.13 0.67
5p12 rs10941679 44706498 MRPS30 A G Yes 0.24 1.07 (1.00 to 1.15) 0.03 1.09 (0.94 to 1.27) 0.24 1.07 (0.99 to 1.15) 0.09 0.78
5q11.2 rs889312 56031884 MAP3K1 A C Yes 0.3 1.04 (0.98 to 1.11) 0.21 0.99 (0.86 to 1.14) 0.90 1.06 (0.98 to 1.14) 0.14 0.44
5q11.3 rs10472076 58184061 RAB3C A G No 0.38 0.99 (0.93 to 1.05) 0.78 1.02 (0.89 to 1.17) 0.78 0.98 (0.92 to 1.05) 0.64 0.66
5q11.3 rs1353747 58337481 PDE4D A C No 0.09 0.95 (0.86 to 1.05) 0.35 1.02 (0.81 to 1.27) 0.88 0.94 (0.83 to 1.05) 0.26 0.52
5q33.3 rs1432679 158244083 A G No 0.45 1.01 (0.95 to 1.07) 0.79 0.92 (0.81 to 1.04) 0.16 1.04 (0.97 to 1.11) 0.30 0.09
6p25.3 rs11242675 1318878 FOXQ1 A G No 0.36 1.01 (0.95 to 1.07) 0.79 1.02 (0.89 to 1.18) 0.75 1.00 (0.93 to 1.08) 0.90 0.83
6p24.3 rs9348512 10456706 TFAP2A C A Yes 0.34 0.85 (0.8 to 0.9) 9.2 × 10−8 0.79 (0.69 to 0.91) 1.1 × 10−3 0.86 (0.8 to 0.92) 3.4 × 10−5 0.32
6p23 rs204247 13722523 RANBP9 A G No 0.44 1.09 (1.03 to 1.15) 3.4 × 10−3 1.08 (0.94 to 1.24) 0.25 1.09 (1.02 to 1.17) 9.7 × 10−3 0.93
6q14 rs17530068 82193109 FAM46A A G Yes 0.25 1.10 (1.03 to 1.18) 7.2 × 10−3 1.07 (0.92 to 1.25) 0.40 1.11 (1.02 to 1.2) 0.01 0.70
6q25.1 rs3757318 151914113 ESR1 G A Yes 0.09 1.15 (1.03 to 1.28) 0.01 1.33 (1.07 to 1.65) 9.1 × 10−3 1.09 (0.96 to 1.24) 0.17 0.12
6q25.1 rs2046210 151948366 ESR1 G A Yes 0.37 1.06 (0.99 to 1.12) 0.07 1.15 (1.00 to 1.33) 0.04 1.03 (0.96 to 1.1) 0.43 0.17
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Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancera (Continued)
7q35 rs720475 144074929 ARHGEF5 G A Yes 0.26 0.99 (0.92 to 1.06) 0.71 0.94 (0.80 to 1.09) 0.41 1.00 (0.93 to 1.08) 0.96 0.45
8p12 rs9693444 29509616 DUSP4 C A Yes 0.33 0.98 (0.93 to 1.05) 0.61 0.92 (0.80 to 1.07) 0.28 1.00 (0.94 to 1.07) 0.94 0.32
8q21.11 rs6472903 76230301 A C Yes 0.16 0.97 (0.90 to 1.05) 0.48 0.95 (0.79 to 1.14) 0.56 0.98 (0.89 to 1.07) 0.66 0.75
8q21.11 rs2943559 76417937 HNF4G A G Yes 0.09 1.10 (1.00 to 1.22) 0.05 1.14 (0.91 to 1.43) 0.27 1.09 (0.97 to 1.23) 0.13 0.77
8q24.21 rs11780156 129194641 MYC G A No 0.19 0.97 (0.90 to 1.04) 0.44 0.95 (0.81 to 1.12) 0.56 0.98 (0.9 to 1.06) 0.60 0.79
8q24.21 rs13281615 128355618 A G Yes 0.43 1.03 (0.97 to 1.09) 0.33 1.05 (0.92 to 1.20) 0.44 1.02 (0.96 to 1.1) 0.51 0.71
9p21.3 rs1011970 22062134 CDKN2B C A Yes 0.17 1.03 (0.95 to 1.11) 0.50 1.11 (0.94 to 1.32) 0.21 1.00 (0.92 to 1.1) 0.95 0.29
9q31.2 rs10759243 110306115 KLF4 C A No 0.29 1.00 (0.94 to 1.06) 0.94 0.94 (0.81 to 1.09) 0.40 1.01 (0.94 to 1.09) 0.69 0.37
9q31.2 rs865686 110888478 KLF4 A C Yes 0.36 0.99 (0.93 to 1.05) 0.75 1.16 (1.01 to 1.34) 0.04 0.94 (0.88 to 1.01) 0.12 0.01
10p12.31 rs7072776 22032942 MLLT10 G A No 0.3 0.99 (0.92 to 1.05) 0.67 0.88 (0.77 to 1.02) 0.08 1.02 (0.94 to 1.09) 0.66 0.09
10p12.31 rs11814448 22315843 DNAJC1 A C No
10q21.2 rs10995190 64278682 ZNF365 G A Yes 0.15 0.94 (0.86 to 1.02) 0.16 0.92 (0.76 to 1.12) 0.43 0.95 (0.86 to 1.04) 0.26 0.84
10q22.3 rs704010 80841148 ZMIZ1 G A Yes 0.38 1.01 (0.95 to 1.07) 0.86 1.02 (0.90 to 1.16) 0.78 1.00 (0.93 to 1.07) 0.96 0.83
10q25.2 rs7904519 114773927 TCF7L2 A G Yes 0.47 1.02 (0.96 to 1.08) 0.56 0.89 (0.78 to 1.01) 0.07 1.06 (0.99 to 1.13) 0.10 0.02
10q26.12 rs2981579 123337335 FGFR2 G A Yes 0.44 1.24 (1.16 to 1.31) 5.4 × 10−12 1.05 (0.92 to 1.20) 0.44 1.29 (1.21 to 1.38) 2.2 × 10−13 7.3 × 10−3
10q26.12 rs11199914 123093901 FGFR2 G A No 0.33 0.95 (0.90 to 1.02) 0.15 0.90 (0.78 to 1.03) 0.13 0.97 (0.9 to 1.04) 0.44 0.33
11p15.5 rs3817198 1909006 LSP1 A G Yes 0.34 1.11 (1.04 to 1.18) 9.3 × 10−4 0.98 (0.85 to 1.13) 0.80 1.15 (1.07 to 1.24) 1.1 × 10−4 0.06
11q13.1 rs3903072 65583066 SNX32 C A No 0.47 0.97 (0.91 to 1.03) 0.34 0.89 (0.78 to 1.01) 0.07 1.00 (0.93 to 1.07) 0.91 0.12
11q13.3 rs554219 69331642 CCND1 C G Yes 0.13 1.09 (1.00 to 1.19) 0.05 0.90 (0.73 to 1.10) 0.31 1.15 (1.04 to 1.26) 5.0 × 10−3 0.04
11q13.3 c11_pos690
88342
69379161 C A Yes 0.06 1.07 (0.95 to 1.21) 0.28 0.85 (0.64 to 1.14) 0.29 1.14 (0.99 to 1.3) 0.08 0.09
11q13.3 rs494406 69344241 G A Yes 0.26 1.05 (0.98 to 1.12) 0.16 1.03 (0.89 to 1.19) 0.66 1.05 (0.98 to 1.14) 0.18 0.80
11q24.3 rs11820646 129461171 BARX2 G A No 0.39 0.92 (0.86 to 0.97) 4.2 × 10−3 0.95 (0.83 to 1.09) 0.45 0.91 (0.84 to 0.97) 5.9 × 10−3 0.56
12p13.1 rs12422552 14413931 ATF7IP G C No 0.28 1.00 (0.93 to 1.06) 0.92 1.02 (0.88 to 1.19) 0.79 0.99 (0.92 to 1.07) 0.79 0.73
12p11.22 rs10771399 28155080 PTHLH A G Yes 0.1 0.89 (0.81 to 0.98) 0.02 0.72 (0.56 to 0.91) 6.6 × 10−3 0.94 (0.84 to 1.05) 0.25 0.05
12q22 rs17356907 96027759 NTN4 A G No 0.3 0.99 (0.93 to 1.06) 0.78 0.95 (0.83 to 1.10) 0.51 1.00 (0.93 to 1.08) 0.96 0.55
12q24.21 rs1292011 115836522 TBX3 A G Yes 0.41 0.92 (0.87 to 0.98) 0.01 1.07 (0.94 to 1.23) 0.29 0.88 (0.82 to 0.95) 5.7 × 10−4 0.01
13q13.1 rs11571833 32972626 BRCA2 T A No 0.03 0.95 (0.78 to 1.16) 0.62 0.91 (0.58 to 1.41) 0.66 0.97 (0.78 to 1.2) 0.76 0.80
14q13.3 rs2236007 37132769 PAX9 G A No 0.21 0.99 (0.92 to 1.07) 0.83 1.20 (1.03 to 1.40) 0.02 0.94 (0.86 to 1.02) 0.13 8.5 × 10−3
14q24.1 rs2588809 68660428 G A No 0.2 1.01 (0.94 to 1.09) 0.82 0.95 (0.80 to 1.13) 0.55 1.03 (0.94 to 1.12) 0.55 0.44
14q24.1 rs999737 69034682 RAD51L1 G A Yes 0.22 0.97 (0.91 to 1.05) 0.48 0.95 (0.81 to 1.11) 0.53 0.98 (0.91 to 1.06) 0.65 0.72
14q32.11 rs941764 91841069 CCDC88C A G No 0.34 1.03 (0.97 to 1.09) 0.39 1.00 (0.88 to 1.14) 0.97 1.04 (0.97 to 1.11) 0.32 0.61
16q12.1a rs3803662 52586341 TOX3 G A Yes 0.29 1.24 (1.16 to 1.32) 6.2 × 10−11 1.12 (0.97 to 1.30) 0.11 1.27 (1.18 to 1.36) 1.5 × 10−10 0.15
16q12.1b rs11075995 53855291 FTO A T No 0.24 1.02(0.95 to 1.09) 0.59 1.01 (0.86 to 1.18) 0.94 1.02 (0.94 to 1.11) 0.57 0.85
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Table 2 Associations of susceptibility loci with overall and estrogen receptor-positive and -negative breast cancera (Continued)
16q12.1b rs17817449 53813367 FTO A C No 0.41 0.94 (0.88 to 1.00) 0.03 1.05 (0.91 to 1.21) 0.49 0.91 (0.85 to 0.97) 6.6 × 10−3 0.08
16q23.2 rs13329835 80650805 CDYL2 A G No 0.24 1.03 (0.96 to 1.11) 0.35 0.94 (0.81 to 1.10) 0.43 1.06 (0.98 to 1.15) 0.13 0.17
17q22 rs6504950 53056471 COX11 G A Yes 0.27 1.04 (0.97 to 1.11) 0.24 1.08 (0.94 to 1.24) 0.27 1.03 (0.95 to 1.11) 0.46 0.54
18q11.2 rs527616 24337424 AQP4 C G No 0.37 0.96 (0.9 to 1.02) 0.19 0.95 (0.83 to 1.08) 0.41 0.96 (0.9 to 1.03) 0.30 0.82
18q11.2 rs1436904 22824665 A C No 0.39 0.96 (0.9 to 1.02) 0.14 1.02 (0.89 to 1.17) 0.79 0.94 (0.87 to 1.01) 0.07 0.30
19p13.11 rs8170 17389704 BABAM1 G A Yes 0.19 0.98 (0.91 to 1.06) 0.62 1.06 (0.90 to 1.25) 0.51 0.96 (0.88 to 1.05) 0.37 0.33
19p13.11 rs4808801 18571141 ELL A G No 0.33 0.97 (0.91 to 1.03) 0.33 1.07 (0.93 to 1.23) 0.33 0.94 (0.87 to 1.01) 0.10 0.11
19q13.31 rs3760982 44286513 KCNN4 G A No 0.46 1.05 (0.99 to 1.12) 0.09 0.97 (0.86 to 1.11) 0.69 1.08 (1.01 to 1.15) 0.03 0.19
21q21.1 rs2823093 16520832 NRIP1 G A Yes 0.27 0.94 (0.88 to 1.01) 0.09 1.07 (0.92 to 1.25) 0.36 0.91 (0.84 to 0.98) 0.02 0.06
22q12.2 rs132390 29621477 EMID1 A G No 0.04 1.17 (1.00 to 1.37) 0.05 0.92 (0.61 to 1.39) 0.70 1.24 (1.04 to 1.49) 0.02 0.22
22q13.1 rs6001930 40876234 SGSM3 A G No 0.10 1.02 (0.92 to 1.12) 0.71 0.94 (0.76 to 1.18) 0.61 1.04 (0.93 to 1.16) 0.48 0.44
aCI, Confidence interval; ER, Estrogen receptor; HR, Hazard ratio; MAF, Mean allele frequency; SNP, Single-nucleotide polymorphism. Results represent BRCA1 and BRCA2 mutation carriers for 74 previously reported
breast cancer (BC) susceptibility variants from population-based studies. P-values <0.05 are shown in bold. bPosition in build 37. cReference allele. cEffect allele. eAssociation in BRCA1 and BRCA2 carriers has been
reported before. fP-value for the difference between the association with ER-positive BC and the association with ER-negative BC.
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Table 3 Comparisons between the associations of 74 breast cancer susceptibility loci in BRCA1 carriers, in BRCA2
carriers, and in population-based studiesa
BRCA1 carriers BRCA2 carriers
Overall ER-positive ER-negative Overall ER-positive ER-negative
BRCA2 carriers Overall 0.46 (0.25 to 0.62)
ER-positive 0.67 (0.52 to 0.78) 0.13 (−0.10 to 0.35)
ER-negative 0.10 (−0.13 to 0.33) 0.46 (0.25 to 0.62)
BCAC Overall 0.43 (0.22 to 0.60) 0.63 (0.47 to 0.75)
ER-positive 0.61 (0.45 to 0.74) 0.16 (−0.07 to 0.38) 0.69 (0.55 to 0.79) 0.13 (−0.11 to 0.35)
ER-negative 0.34 (0.12 to 0.53) 0.59 (0.42 to 0.72) 0.39 (0.17 to 0.57) 0.28 (0.05 to 0.48)
aER, Estrogen receptor. Data are intraclass correlation coefficients and 95% confidence intervals, which describe associations with overall breast cancer as well as
by ER status. Data are derived from published studies by the Breast Cancer Association Consortium (BCAC).
Kuchenbaecker et al. Breast Cancer Research  (2014) 16:3416 Page 13 of 270.72) (Figure 1E). However, the ER-negative breast cancer
log HR estimates in BRCA2 carriers were less strongly cor-
related with the corresponding estimates in BRCA1 car-
riers (ICC = 0.46, 95% CI: 0.25 to 0.62) (Figure 1D) and in
BCAC (ICC = 0.28, 95% CI: 0.05 to 0.48) (Figure 1F).
There was no evidence that the ICC was different from 0
for the comparison between ER-positive associations in
BRCA1 carriers with ER-negative associations in BRCA2
carriers and vice versa (Additional file 1: Figure S4B,C).
Similarly, there was no significant correlation between log
OR estimates for ER-positive breast cancer in BCAC with
log HR estimates for ER-negative breast cancer in BRCA1
and BRCA2 carriers (Additional file 1: Figures S5B and
S6B). There was only moderate correlation between log
OR estimates for ER-negative breast cancer in the general
population and log HR estimates for ER-positive breast
cancer in BRCA1 and BRCA2 carriers (ICC = 0.39 and
ICC = 0.34, respectively) (Additional file 1: Figures S5C
and S6C).
Associations by subtype with all single-nucleotide
polymorphisms on iCOGS
Variants in or near the known breast cancer susceptibil-
ity loci TERT, ESR1 and 19p13.11 showed strong associ-
ations (P <10−6) with at least one of the categories in all
subtype analyses in BRCA1 carriers. The same was true
for SNPs in FGFR2 and TOX3 in BRCA2 carriers.
Variants on the iCOGS array that exhibited associations
at P <10−6 with any of the breast cancer subtypes of ER-,
PR-, HER2-positive or -negative and TN breast tumors are
shown in Table 4. All the variants associated with ER-
positive or ER-negative breast cancer at P <10−6 were
located within known breast cancer susceptibility loci.
Similar associations were observed with PR-positive and
PR-negative breast cancer for BRCA1 carriers. A previ-
ously unreported SNP at 2p13.2 was associated with
HER2-positive breast cancer in BRCA1 carriers. In BRCA2
carriers, two previously unreported variants showed
evidence of association in the analysis by PR status.Furthermore, SNPs at 8q12.1 near TOX were associated
with HER2-positive cancer in BRCA2 carriers. Only SNPs
in the known breast cancer susceptibility loci FGFR2 and
TOX3 were associated with non-TN breast cancer in
BRCA2 carriers, and none were associated with TN breast
cancer at P <10−6.
A SNP at 7q36 was associated with ductal subtype for
BRCA1 carriers (Table 5). Two loci were associated with
lobular breast cancer for BRCA2 carriers: 11q23.3 and
Xp11.23.
There was one novel association with high-grade tu-
mors in BRCA1 carriers (Table 6). Three previously un-
reported variants were associated with breast cancer
nodal status in BRCA1 carriers: SNPs at 4q24 in the
TET2 gene, at 5q32 in the SH3RF2 gene and at 7p22 in
an intron of NXPH1. For BRCA2 carriers, only SNPs in
FGFR2 and TOX3 exhibited associations at P <10−6 with
breast cancer nodal status or histological grade.
Discussion
This is the first comprehensive report, to our know-
ledge, of the associations of genetic variants with risk
of developing breast cancer by tumor subtypes in
BRCA1 and BRCA2 carriers. We evaluated the associa-
tions with ER, PR and HER2 status; morphologic sub-
type (ductal or lobular); histological grade; and lymph
node status.
Prior to this study, variants at five loci (5p15.33,
6q25.1, 11p15.5, 12p11.22 and 16q12.1) had been shown
to be associated with breast cancer risk for both BRCA1
and BRCA2 carriers; variants at four additional loci were
known to be associated with breast cancer risk for
BRCA1 carriers only (1q32.1, 10q25.2, 14q24.1 and
19p13.11); and variants at six additional loci were known
to be associated with risk for BRCA2 carriers (3p24.1,
5p12, 6p24.3, 10q26.12, 11q13 and 12q24.21) [6,7,10].
Among the 43 breast cancer susceptibility variants
that had not previously been evaluated in mutation
carriers, we observed six associations with breast cancer at
HRs for ER-positive HRs for ER-negative
B
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Figure 1 Estrogen receptor-positive and -negative log hazard ratio estimates in the general population and in BRCA1 and BRCA2
carriers. Dots represent the association of 74 previously reported breast cancer susceptibility single-nucleotide polymorphisms with estrogen
receptor (ER)-positive breast cancer (A–C) and ER-negative breast cancer (D–F). (A) and (D) compare associations between BRCA1 and BRCA2
carriers, (B) and (E) between the general population and BRCA1 carriers and (C) and (F) between the general population and BRCA2 carriers.
Association results for the general population were taken from reports published by the Breast Cancer Association Consortium (BCAC) [8-10,16].
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Table 4 Associations with tumor subtypesa
Affected by subtype, n (MAF) Positive Negative
Subtype Sample SNP Locus Positionb Nearby
gene
Refc Effd Reportede Positive Negative Unknown Number
unaffected
(MAF)
HR
(95% CI)
P-value HR
(95% CI)
P-value Phet-value
f
ER status BRCA1
carriers
rs10069690 5p15.33 1332790 TERT G A Yes 819
(0.27)
2,635
(0.3)
4,331
(0.3)
7,449
(0.26)
1.09
(0.98 to
1.22)
0.09 1.24
(1.18 to
1.31)
2.7 × 10−15 0.04
rs2046210 6q25.1 151990059 C6orf97 G A Yes 819
(0.36)
2,639
(0.39)
4,338
(0.38)
7,453
(0.35)
1.04
(0.94 to
1.15)
0.42 1.2
(1.15 to
1.26)
2.8 × 10−13 0.01
rs2811708 9p21 21963422 CDKN2A/B C A Yes 816
(0.24)
2,634
(0.31)
4,336
(0.28)
7,445
(0.28)
0.82
(0.73 to
0.91)
2.9 × 10−4 1.13
(1.07 to
1.19)
7.3 × 10−6 3.9 × 10−7
rs45631579 10q26 123328965 FGFR2 A G Yes 819
(0.48)
2,639
(0.4)
4,337
(0.42)
7,455
(0.41)
1.29
(1.17 to
1.43)
2.6 × 10−7 0.92
(0.87 to
0.96)
4.7 × 10−4 5.1 × 10−9
rs2590275 12p12 28057334 PTHLH G C Yes 819
(0.26)
2,639
(0.25)
4,338
(0.26)
7,454
(0.28)
0.92
(0.83 to
1.03)
0.14 0.87
(0.82 to
0.92)
5.3 × 10−7 0.34
rs2363956 19p13.11 17255124 ANKLE1 C A Yes 819
(0.47)
2,635
(0.53)
4,334
(0.52)
7,447
(0.48)
0.98
(0.89 to
1.08)
0.71 1.25
(1.19 to
1.31)
6.4 × 10−20 1.6 × 10−5
BRCA2
carriers
rs2162540 10q26 123342126 FGFR2 A G Yes 1450
(0.47)
426
(0.41)
2,348
(0.44)
3,783
(0.38)
1.34
(1.25 to
1.43)
3.6 × 10−16 1.08
(0.94 to
1.23)
0.27 6.1 × 10−3
rs17271951 16q12.1 51095541 TOX3 A G Yes 1490
(0.32)
434
(0.28)
2,397
(0.3)
3,879
(0.25)
1.29
(1.2 to
1.39)
8.4 × 10−12 1.14
(0.99 to
1.31)
0.08 0.14
PR status BRCA1
carriers
rs10069690 5p15.33 1332790 TERT G A Yes 662
(0.27)
2,481
(0.29)
4,642
(0.3)
7,449
(0.26)
1.10
(0.98 to
1.24)
0.09 1.24
(1.17 to
1.3)
1.3 × 10−14 0.11
rs2046210 6q25.1 151990059 C6orf97 G A Yes 662
(0.37)
2,485
(0.39)
4,649
(0.38)
7,453
(0.35)
1.09
(0.98 to
1.21)
0.12 1.18
(1.13 to
1.24)
2.0 × 10−11 0.19
rs45631626 10q26 123327325 FGFR2 G A Yes 662
(0.49)
2,485
(0.4)
4,647
(0.42)
7,455
(0.42)
1.33
(1.2 to
1.48)
1.3 × 10−7 0.92
(0.88 to
0.97)
9.6 × 10−4 5.3 × 10−9
rs2590275 12p12 28057334 PTHLH G C Yes 662
(0.26)
2,485
(0.25)
4,649
(0.26)
7,454
(0.28)
0.92
(0.82 to
1.03)
0.16 0.87
(0.82 to
0.92)
8.2 × 10−7 0.45
rs8100241 19p13.11 17253894 ANKLE1 G A Yes 657
(0.51)
2,473
(0.47)
4,628
(0.48)
7,420
(0.52)
0.98
(0.88 to
1.09)
0.71 0.81
(0.78 to
0.85)
1.8 × 10−17 2.4 × 10−3
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Table 4 Associations with tumor subtypesa (Continued)
BRCA2
carriers
rs10017576 4q28.3 139799629 G A No 1099
(0.38)
591
(0.43)
2,639
(0.41)
3,880
(0.43)
0.83
(0.77 to
0.89)
8.9 × 10−7 1.02
(0.92 to
1.14)
0.67 2.7 × 10−3
rs4376461 8p12 32822117 NRG1 C A No 1099
(0.15)
591
(0.10)
2,640
(0.14)
3,881
(0.15)
1.00
(0.9 to
1.12)
0.93 0.6
(0.5 to
0.73)
2.4 × 10−7 1.4 × 10−5
rs45631588 10q26 123341292 FGFR2 A G Yes 1099
(0.47)
591
(0.43)
2,640
(0.45)
3,881
(0.39)
1.33
(1.23 to
1.44)
2.7 × 10−13 1.15
(1.03 to
1.28)
0.01 0.04
rs17271951 16q12.1 51095541 TOX3 A G Yes 1099
(0.32)
591
(0.28)
2,631
(0.3)
3,879
(0.25)
1.32
(1.21 to
1.43)
4.3 × 10−11 1.14
(1.01 to
1.29)
0.03 0.07
HER2
status
BRCA1
carriers
rs17008885 2p13.2 73303647 SMYD5 T A No 182
(0.19)
1,816
(0.3)
5,799
(0.3)
7,455
(0.31)
0.54
(0.43 to
0.69)
7.8 × 10−7 0.99
(0.95 to
1.04)
0.78 3.8 × 10−6
rs10069690 5p15.33 1332790 TERT G A Yes 181
(0.23)
1,813
(0.29)
5,791
(0.3)
7,449
(0.26)
0.9
(0.71 to
1.13)
0.36 1.24
(1.18 to
1.3)
3.4 × 10−17 0.01
rs2046210 6q25.1 151990059 C6orf97 G A Yes 182
(0.39)
1,816
(0.4)
5,798
(0.38)
7,453
(0.35)
1.12
(0.91 to
1.38)
0.29 1.17
(1.11 to
1.22)
1.5 × 10−10 0.71
rs10843055 12p12 28063088 PTHLH A C Yes 171
(0.06)
1,743
(0.06)
5,615
(0.06)
7,234
(0.07)
0.79
(0.52 to
1.2)
0.26 0.79
(0.72 to
0.87)
6.2 × 10−7 0.99
rs4808616 19p13.11 17264033 ANKLE1 C A Yes 176
(0.35)
1,782
(0.32)
5,706
(0.32)
7,339
(0.28)
1.37
(1.11 to
1.69)
3.8 × 10−3 1.2
(1.14 to
1.26)
6.8 × 10−13 0.25
BRCA2
carriers
rs4305889 8q12.1 60352785 TOX A G No 121
(0.18)
845
(0.09)
3,353
(0.11)
3,874
(0.1)
2.04
(1.53 to
2.71)
8.7 × 10−7 0.96
(0.85 to
1.08)
0.47 1.0 × 10−5
rs45631588 10q26 123341292 FGFR2 A G Yes 121
(0.45)
847
(0.46)
3,362
(0.45)
3,881
(0.39)
1.27
(0.98 to
1.63)
0.07 1.28
(1.19 to
1.37)
2.1 × 10−12 0.95
rs3817197 11p15.5 1862750 LSP1 G A Yes 121
(0.55)
847
(0.44)
3,353
(0.45)
3,877
(0.47)
1.30
(1.02 to
1.64)
0.03 0.84
(0.79 to
0.9)
9.1 × 10−7 1.3 × 10−3
rs17271951 16q12.1 51095541 TOX3 A G Yes 121
(0.29)
847
(0.31)
3,353
(0.3)
3,879
(0.25)
1.10
(0.85 to
1.41)
0.47 1.27
(1.18 to
1.37)
6.9 × 10−11 0.3
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Table 4 Associations with tumor subtypesa (Continued)
Triple-
negativeg
BRCA1
carriers
rs10069690 5p15.33 1332790 TERT G A Yes 579
(0.27)
1,307
(0.3)
5,899
(0.3)
7,449
(0.26)
1.06
(0.94 to
1.19)
0.34 1.27
(1.2 to
1.36)
5.2 × 10−14 0.02
rs2046210 6q25.1 151990059 C6orf97 G A Yes 580
(0.37)
1,310
(0.41)
5,906
(0.38)
7,453
(0.35)
1.01
(0.91 to
1.13)
0.79 1.23
(1.16 to
1.31)
5.5 × 10−12 6.8 × 10−3
rs9512729 13q12.2 26974865 LNX2 G A No 580
(0.34)
1,309
(0.43)
5,902
(0.41)
7,454
(0.41)
0.76
(0.69 to
0.85)
9.1 × 10−7 1.08
(1.02 to
1.15)
0.01 1.2 × 10−6
rs8100241 19p13.11 17253894 ANKLE1 G A Yes 577
(0.5)
1,304
(0.46)
5,877
(0.48)
7,420
(0.52)
0.94
(0.85 to
1.04)
0.22 0.81
(0.76 to
0.86)
2.4 × 10−13 0.03
BRCA2
carriers
rs2162540 10q26 123342126 FGFR2 A G Yes 735
(0.46)
133
(0.36)
3,356
(0.44)
3,783
(0.38)
1.39
(1.29 to
1.49)
9.8 × 10−20 0.83
(0.67 to
1.03)
0.10 4.0 × 10−5
rs1362548 16q12.1 51121452 TOX3 C G Yes 760
(0.32)
136
(0.29)
3,434
(0.31)
3,881
(0.26)
1.26
(1.17 to
1.36)
1.0 × 10−9 1.18
(0.94 to
1.49)
0.16 0.63
aCI, Confidence interval; HR, Hazard ratio; MAF, Mean allele frequency. Single-nucleotide polymorphisms (SNPs) associated at P <10−6 with breast cancer by tumor estrogen receptor (ER) status, progesterone receptor
(PR) status, human epidermal growth factor receptor 2 (HER2) status or triple-negative (negative for ER, PR and HER2) are shown. The most strongly associated SNP from each locus is reported. bPosition in build 36.
cReference allele. dEffect allele. eVariant located in previously reported breast cancer susceptibility locus. fP-value for the difference in association between subtype positive and subtype negative breast cancer (for
example, ER-positive vs ER-negative). gNon–triple negative was considered as “positive” and triple-negative as “negative.”
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Table 5 Associations with ductal and lobular breast cancera
N tumors with
morphology (MAF)
Other morphology Tumors with
morphology
Subtype Sample SNP Locus Positionb Nearby
gene
Refc Effd Reportede Present Other Unknown Number
unaffected
(MAF)
HR (95% CI) P-value HR (95% CI) P-value Phet-value
f
Ductal BRCA1
carriers
rs10069690 5p15.33 1332790 TERT G A Yes 3,155
(0.29)
847
(0.30)
3,783
(0.30)
7,449 (0.26) 1.23
(1.11 to 1.36)
7.3 × 10−5 1.20
(1.14 to 1.26)
2.0 × 10−11 0.67
rs11155803 6q25.1 151987362 C6orf97 A G Yes 3,159
(0.36)
848
(0.35)
3,786
(0.36)
7,452 (0.32) 1.13
(1.03 to 1.25)
0.01 1.17
(1.11 to 1.23)
4.6 × 10−10 0.58
rs10252939 7q36 155587448 A G No 3,159
(0.28)
849
(0.33)
3,789
(0.29)
7,455 (0.32) 1.08
(0.98 to 1.19)
0.14 0.87
(0.82 to 0.91)
1.0 × 10−7 2.7 × 10−4
rs8100241 19p13.11 17253894 ANKLE1 G A Yes 3,137
(0.48)
844
(0.49)
3,777
(0.47)
7,420 (0.52) 0.87
(0.79 to 0.95)
2.8 × 10−3 0.84
(0.8 to 0.88)
1.5 × 10−13 0.51
BRCA2
carriers
rs2162540 10q26 123342126 FGFR2 A G Yes 1,728
(0.45)
458
(0.44)
2,038
(0.44)
3,783 (0.38) 1.24
(1.08 to 1.42)
1.8 × 10−3 1.30
(1.21 to 1.39)
3.1 × 10−14 0.55
rs1362548 16q12.1 51121452 TOX3 C G Yes 1,770
(0.3)
473
(0.32)
2,087
(0.31)
3,881 (0.26) 1.32
(1.15 to 1.51)
4.8 × 10−5 1.23
(1.15 to 1.32)
7.3 × 10−9 0.36
Lobular BRCA2
carriers
rs2186703 11q23.3 115265717 RPL15P15 A C No 188
(0.07)
2,055
(0.03)
2,087
(0.04)
3,881 (0.03) 1.09
(0.93 to 1.27)
0.29 2.54
(1.78 to 3.62)
2.8 × 10−7 1.5 × 10−5
rs55998524 Xp11.23 51082075 NUDT10 C G No 188
(0.11)
2,054
(0.05)
2,086
(0.06)
3,880 (0.05) 0.96
(0.83 to 1.1)
0.54 2.42
(1.77 to 3.32)
3.6 × 10−8 7.0 × 10−8
aCI, Confidence interval; HR, Hazard ratio; MAF, Mean allele frequency. Single-nucleotide polymorphisms (SNPs) associated at P <10−6 with ductal carcinomas and, for BRCA2 mutation carriers, lobular carcinomas are
shown. The most strongly associated SNP from each locus is reported. bPosition in build 36. cReference allele. dEffect allele. eVariant located in previously reported breast cancer susceptibility locus. fP-value for the
difference in SNP association between ductal breast tumors and non-ductal breast tumors and for lobular breast tumors and non-lobular breast tumors.
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Table 6 Associations with grade and lymph node statusa
Affected by subtype, n (MAF) Low-grade/
no nodal
involvement
High grade/
nodal
involvement
Subtype Sample SNP Locus Positionb Nearby
gene
Refc Effd Reportede High-
grade/
node-
positive
Low-
grade/
node-
negative
Unknown Number
unaffected
(MAF)
HR
(95% CI)
P-value HR
(95% CI)
P-value Phet-value
f
Grade 3 BRCA1
carriers
rs17651413 2q33.1 202677054 KIAA2012 A G No 2,495
(0.12)
655
(0.11)
4,644
(0.13)
7,454 (0.11) 1.01
(0.86 to
1.2)
0.86 1.20
(1.12 to
1.29)
8.4 × 10−7 0.08
rs10069690 5p15.33 1332790 TERT G A Yes 2,493
(0.3)
654
(0.29)
4,638
(0.3)
7,449 (0.26) 1.15
(1.02 to
1.29)
0.02 1.22
(1.16 to
1.29)
2.4 × 10−13 0.39
c6_pos1519
89450
6q25.1 151989450 C6orf97 G A Yes 2,497
(0.11)
655
(0.08)
4,645
(0.1)
7,455 (0.08) 1.01
(0.83 to
1.24)
0.91 1.31
(1.21 to
1.42)
2.2 × 10−11 0.02
rs8100241 19p13.11 17253894 ANKLE1 G A Yes 2,483
(0.48)
653
(0.52)
4,622
(0.48)
7,420 (0.52) 0.95
(0.86 to
1.05)
0.36 0.82
(0.78 to
0.86)
2.2 × 10−16 0.01
BRCA2
carriers
rs45631588 10q26 123341292 FGFR2 A G Yes 839
(0.44)
813
(0.48)
2,678
(0.44)
3,881 (0.39) 1.36
(1.24 to
1.49)
7.4 × 10−11 1.19
(1.09 to
1.3)
1.7 × 10−4 0.06
rs35850695 16q12.1 51131844 TOX3 G A Yes 839
(0.32)
813
(0.3)
2,678
(0.3)
3,881 (0.26) 1.2
(1.09 to
1.33)
3.0 × 10−4 1.31
(1.19 to
1.44)
4.0 × 10−8 0.26
Nodes BRCA1
carriers
rs1498125 4q24 106412012 TET2 A G No 1,103
(0.2)
2,274
(0.23)
4,419
(0.22)
7,455 (0.2) 1.18
(1.1 to
1.25)
4.4 × 10−7 0.98
(0.89 to
1.09)
0.74 5.7 × 10−3
rs10069690 5p15.33 1332790 TERT G A Yes 1,100
(0.3)
2,271
(0.29)
4,414
(0.3)
7,449 (0.26) 1.19
(1.12 to
1.26)
6.2 × 10−9 1.24
(1.13 to
1.35)
2.0 × 10−6 0.5
rs11743632 5q32 145389263 SH3RF2 G A No 1,103
(0.31)
2,274
(0.37)
4,418
(0.36)
7,453 (0.37) 1.05
(0.99 to
1.11)
0.1 0.8
(0.74 to
0.87)
2.3 × 10−7 6.9 × 10−7
rs9383936 6q25.1 151986307 C6orf97 G A Yes 1,103
(0.11)
2,274
(0.09)
4,420
(0.1)
7,455 (0.08) 1.16
(1.06 to
1.28)
1.3 × 10−3 1.41
(1.24 to
1.6)
1.3 × 10−7 0.03
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Table 6 Associations with grade and lymph node statusa (Continued)
rs2349485 7p22 8517481 NXPH1 A C No 1,091
(0.37)
2,249
(0.34)
4,374
(0.34)
7,398 (0.37) 0.87
(0.82 to
0.92)
8.5 × 10−7 0.97
(0.90 to
1.06)
0.53 0.03
rs11669059 19p13.11 17261453 ANKLE1 A G Yes 1,103
(0.41)
2,273
(0.4)
4,418
(0.39)
7,452 (0.43) 0.85
(0.81 to
0.9)
2.9 × 10−9 0.86
(0.80 to
0.93)
2.6 × 10−4 0.81
BRCA2
carriers
rs2981578 10q26 123330301 FGFR2 A G Yes 795
(0.44)
1,047
(0.48)
2,428
(0.47)
3,819 (0.52) 0.87
(0.8 to
0.94)
7.4 × 10−4 0.75
(0.68 to
0.82)
1.0 × 10−9 0.02
rs35850695 16q12.1 51131844 TOX3 G A Yes 804
(0.31)
1,068
(0.3)
2,458
(0.3)
3,881 (0.26) 1.22
(1.12 to
1.33)
8.5 × 10−6 1.30
(1.18 to
1.44)
2.6 × 10−7 0.36
aCI, Confidence interval; HR, Hazard ratio; MAF, Mean allele frequency. Single-nucleotide polymorphisms (SNPs) associated at P <10−6 with high- or low-grade breast tumors and lymph node–positive or lymph
node–negative breast cancer are shown. The most strongly associated SNPs from each locus are reported. bPosition in build 36. cReference allele. dEffect allele. eVariant located in previously reported breast cancer
susceptibility locus. fP-value for the difference in association between high-grade breast cancer and low-grade breast cancer for grade 3 and for the association with lymph node–positive breast cancer and lymph
node–negative breast cancer.
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Kuchenbaecker et al. Breast Cancer Research  (2014) 16:3416 Page 21 of 27P <0.05 in BRCA1 carriers (5p33.3, 8q24.21, 11q24.3,
12q22, 16q12.1b and 22q13.1) and three in BRCA2 car-
riers (6p23, 11q24.3 and 16q12.1b).
After stratifying by ER status, we observed additional as-
sociations that were not seen for overall breast cancer.
Among the 43 susceptibility variants that were evaluated
in mutation carriers for the first time, we identified two
additional associations in BRCA1 carriers when stratifying
by ER status (3q26.1, 6p25.3) and four in BRCA2 carriers
(2q24, 14q13.3, 19q13.3, 22q12.2). Population-based
studies have shown that seven of the 74 breast cancer sus-
ceptibility variants display stronger associations with ER-
negative disease in the general population [9]. Consistent
with these findings, SNPs at 1q32.1 (MDM4), 5p15.33,
6q25.1 and 19p13 were associated with ER-negative breast
cancer in BRCA1 carriers and SNPs at 2p24.1, 5p15.33
and 6q25.1 in BRCA2 carriers. No data were available for
the SNP at 20q11.
We were able to confirm most of the associations with
ER and PR subtypes of the 12 SNPs reported in the previ-
ous smaller CIMBA study [15]. In addition, two variants
from that analysis now displayed evidence at P <0.05:
rs13387042 at 2q35 with ER-positive breast cancer in
BRCA1 carriers and rs2046210 at 6q25.1 with ER-negative
breast cancer in BRCA2 carriers.
We also evaluated the associations of the 74 previously
reported breast cancer susceptibility loci with other breast
cancer subtypes. Variants at 5p15.33 (TERT), 6q25.1
(ESR1) and 19p13.11 showed associations in all subtype
analyses for BRCA1 carriers. These are the most strongly
associated loci for overall breast cancer in BRCA1 carriers,
but they had not previously been investigated for their
roles in subtypes other than ER. Variants at these three
loci were associated with ER-, PR- and HER2-negative and
TN subtypes. These variants were also associated with risk
of high-grade tumors, with some suggestive evidence that
this association was different from the association with
grades 1 and 2 tumors for SNPs at ESR1 and 19p13. The
three loci were associated with ductal as well as non-
ductal subtypes and node-positive as well as node-
negative breast cancer. For BRCA2 carriers, SNPs at loci
10q26 (FGFR2) and 16q12.1 (TOX3) were associated with
all subtypes of breast cancer. SNPs at FGFR2 and TOX3
have consistently been associated with overall and with
ER-positive breast cancer in population-based cases [25]
as well as in BRCA1/2 carriers [15]. Furthermore, SNPs at
these two loci were associated with PR-positive and
HER2-negative disease. There was no evidence for a differ-
ence in HR estimates by tumor grade, nodal involvement
or morphologic subtype (ductal).
It is important to note that for each of the 74 known
loci considered, we evaluated only the associations for
the specific SNPs that have been reported by the BCAC.
We have not considered all genetic variants within agiven region. Therefore, we cannot rule out the possibil-
ity that more strongly associated variants exist at these
loci than the SNPs reported here. Future fine-mapping
efforts in conjunction with BCAC analyses should clarify
this. Such studies may also identify the causal variant
and together with subsequent functional studies gather
insights about the functional mechanisms causing these
association signals. This in turn may yield insights about
the etiology of breast cancer in BRCA1 and BRCA2
carriers.
We compared HRs for the association with overall
breast cancer and ER-positive and ER-negative breast
cancer for all the 74 known breast cancer susceptibility
variants between BRCA1 carriers, BRCA2 carriers and
population-based studies using published data from
BCAC. Although only some of these variants were asso-
ciated at P <0.05 with breast cancer in mutation carriers
as outlined above, there was nevertheless strong correl-
ation between the HRs for overall breast cancer from
the general population and those from BRCA2 carriers,
and moderate correlation between the HRs from BRCA1
carriers and from BCAC. These results suggest that
many of these variants may also be associated with
breast cancer risk for mutation carriers, but the power
to detect statistically significant associations in mutation
carriers is low. These variants could be employed in risk
prediction models for mutation carriers. Future studies
should be aimed at assessing the associations of the
combined effects of the SNPs in mutation carriers in
terms of polygenic risk scores.
We used these comparisons to assess the hypothesis
that observed differences in the associations between
BRCA1 and BRCA2 carriers and the general population
are mediated by ER status. The smaller correlation be-
tween the association estimates for BRCA1 carriers and
both BCAC and BRCA2 carriers compared with those
between BCAC and BRCA2 carriers is consistent with
this hypothesis. Moreover, we found stronger correla-
tions between the HRs for ER-positive disease in all
three two-way comparisons (ICC = 0.61 to 0.69). The
correlation between ORs for ER-negative disease from
BCAC and HRs for ER-negative disease from BRCA1
carriers was also strong (ICC = 0.59). Correlations di-
minished when comparing HR estimates for ER-positive
with estimates for ER-negative breast cancer; most of
them were not significantly different from zero. This
finding suggests that, to a large extent, the difference in
SNP association patterns is due to mediating effects of
tumor ER status. Under such a model, the effects of com-
mon breast cancer susceptibility variants and of BRCA1
and BRCA2 mutations on breast cancer risk would be
multiplicative, after taking into account tumor ER status.
As BRCA1 carriers are more likely to develop ER-negative
disease, SNPs associated with this subtype will be more
Kuchenbaecker et al. Breast Cancer Research  (2014) 16:3416 Page 22 of 27informative in models to predict overall breast cancer risk
in these women, whereas SNPs associated with ER-
positive disease will be more useful in BRCA2 carriers.
Furthermore, ER-specific SNP associations could be used
to provide separate estimates of ER-negative and ER-
positive breast cancer risk for mutation carriers. This un-
derstanding allows the development of more refined models
and is critical to the provision of accurate information to
women considering more targeted preventive options.
However, the fact that the correlations between the
HR estimates matched for ER status were smaller than 1
implies that there were still some differences in the asso-
ciations after accounting for ER status. This could be
due to sampling error or to real differences in genetic
associations between BRCA1 and BRCA2 carriers and
the general population. There are examples for such dif-
ferences: BRCA1 and BRCA2 carrier-specific modifiers,
such as the recently identified variant at 6p24, which
was associated with breast cancer risk only in BRCA2
carriers [6], and the ovarian cancer susceptibility locus
4q32, which appeared to modify ovarian cancer risk only
for BRCA1 carriers [7]. In addition, an ovarian cancer
susceptibility locus 17q11.2 identified through population-
based data has been shown to display a consistent associ-
ation in BRCA2 carriers, whereas an association of similar
magnitude has been ruled out in BRCA1 carriers [26]. The
extent to which genetic susceptibility to breast cancer in
mutation carriers and in the general population is shared,
as well as the extent to which it is mediated by ER status,
need to be quantified systematically by future studies.
We also assessed the associations of over 200,000
SNPs on the iCOGS array. We identified several variants
not previously reported that were associated with breast
cancer at P <10−6 in the analyses by PR status, HER sta-
tus, TN phenotype, histological grade, nodal involve-
ment, ductal and lobular morphologic subtypes. In the
absence of P-values at genome-wide significance levels
for these associations to account for multiple testing,
these associations require confirmation through by gath-
ering additional data.
Although this is the largest study of its kind, the statis-
tical power to detect associations of variants conferring
small effects with specific tumor characteristics may be
low, owing to the limited data available. Future studies
of additional BRCA1 and BRCA2 carriers with detailed
tumor pathology information on new and previously re-
cruited mutation carriers are needed. In this study,
tumor pathology information was retrieved primarily
from medical records. Despite extensive efforts, it is dif-
ficult to control the quality of these data. If there is low
reproducibility in the classification of tumor characteris-
tics for some samples, this could potentially add to the
sampling error and make it more difficult to detect
subtype-specific associations.Conclusions
We have identified additional genetic modifiers of breast
cancer risk for mutation carriers among reported breast
cancer susceptibility loci. Large differences in absolute
risk are expected between mutation carriers who carry
many and mutation carriers who carry few risk alleles of
modifying variants [6,7]. Therefore, in combination with
previously identified modifiers, these variants may be of
value for cancer risk prediction. Moreover, our results
show that, to a large extent, the differences in breast
cancer associations of known breast cancer susceptibility
loci between BRCA1 and BRCA2 carriers and the gen-
eral population are due to differences in the prevalence
of tumor subtypes in BRCA1 and BRCA2 carriers. Esti-
mates of the risks associated with these genetic variants
based on large population-based association studies are
likely to be applicable also to mutation carriers after tak-
ing ER status into account. Our results thus have impli-
cations for developing risk prediction models for breast
cancer subtype-specific risks in mutation carriers that
incorporate the effects of these SNPs.Additional file
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